Lifeward Ltd. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Lifeward Ltd. on January 28, 2026. The filing primarily addresses updates to the proposed corporate governance structure following a Share Purchase Agreement with Oramed Pharmaceuticals, Inc. ("Oramed") and Oratech Pharma, Inc. ("Oratech"), and announces an upcoming Extraordinary General Meeting of Shareholders.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses on corporate governance and transactional approvals rather than financial performance results.
Material Changes
- Board Composition Update: The Company revised its prior disclosure regarding the post-closing Board of Directors. The Board is now expected to consist of eight (8) members: three designated by Lifeward, three by Oramed, and two External Directors. This is an increase from the previously disclosed six-member structure.
- Shareholder Meeting Announcement: An Extraordinary General Meeting is scheduled for March 12, 2026, to approve critical transaction-related matters.
Guidance, Outlook, and Material Matters
The filing details the agenda for the March 12, 2026, shareholder meeting, which includes:
- Share Issuance Approval: Approval for issuing Ordinary Shares to Oramed as consideration for the acquisition of 100% of Oratech, as well as shares issuable upon the exercise of warrants and conversion of secured convertible notes.
- Ownership Thresholds: The issuance is expected to result in Oramed holding at least 45.00% and potentially over 49.99% of the Company's outstanding voting power, potentially constituting a "change of control" under Nasdaq rules.
- Director Elections: Approval of two External Directors to serve three-year terms effective upon the closing of the Oratech Acquisition.
- Compensation and Plans: Approval of compensation for External Directors, an increase in shares available under the 2025 Incentive Compensation Plan, and a specific equity grant to CEO Mark Grant.
- Auditor Reappointment: Reappointment of Kost Forer Gabbay & Kasierer (Ernst & Young Global) as the independent registered public accounting firm for the year ending December 31, 2026.
Investor Verification Checklist
- Verify the final terms of the Share Purchase Agreement between Lifeward, Oramed, and Oratech.
- Review the Definitive Proxy Statement (Schedule 14A) expected to be filed on or about February 9, 2026, for detailed financial implications of the share issuance.
- Confirm the exact percentage of voting power Oramed will hold post-closing and the specific Nasdaq Listing Rule 5635 compliance measures.
- Assess the impact of the potential "change of control" on existing shareholder rights and company strategy.
- Monitor the outcome of the shareholder vote on March 12, 2026, as the transaction closing is contingent upon these approvals.